~~<i id='B813B94E71'><strike id='B813B94E71'><tt id='B813B94E71'><pre id='B813B94E71'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

focus

author：leisure time 2025-08-12 06:42:23 - browse：71

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： GSK Flovent asthma inhalers replaced by authorized generics

focus

hotspot

focus

leisure time

knowledge

KeishaOkaforforSTATClinicaltrialsarecriticaltoadvancinglifesavingmedicationsandtreatments.ButtheU.S.

WSS

Feng Zhang CRISPR delivery startup lays off quarter of staff

U.K. sequencing study surfaces new findings about tumor DNA

Feng Zhang, Grail founder join forces on new gene editing startup

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Food makers to regulators: Ultra

Chronically ill young patients struggle to find fertility info

entertainment

focus

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Why psychiatrists like me stop taking insurance

Hepatitis C has a cure — but many Americans still lack access to it

How a scoliosis diagnosis changed the life of one young dancer

Supreme Court strikes down use of affirmative action

Food makers tried to stack nutrition panel with preferred experts

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

3 trends to watch in health tech's hiring outlook for 2024

BioMarin wins approval for gene therapy to treat hemophilia A

A common UTI test for kids haunts adults as a traumatic 'nightmare'

focus

How medical schools plan to diversify without affirmative action

How housing is health care on Long Island

Food makers tried to stack nutrition panel with preferred experts

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

FDA approves updated Covid vaccines

White House touts steps to stem shortages of cancer treatments

hotspot

focus

leisure time

knowledge